FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $12,000 | -91.0% | 209 | -94.7% | 0.00% | -83.3% |
| Q3 2021 | $133,000 | +923.1% | 3,909 | +768.7% | 0.01% | +500.0% |
| Q2 2021 | $13,000 | +8.3% | 450 | -30.8% | 0.00% | 0.0% |
| Q1 2021 | $12,000 | -92.5% | 650 | -81.8% | 0.00% | -87.5% |
| Q4 2020 | $159,000 | +1345.5% | 3,580 | -12.7% | 0.01% | +700.0% |
| Q3 2020 | $11,000 | -75.6% | 4,100 | +36.7% | 0.00% | -66.7% |
| Q2 2020 | $45,000 | +25.0% | 3,000 | -73.0% | 0.00% | +50.0% |
| Q1 2020 | $36,000 | +100.0% | 11,100 | +37.0% | 0.00% | +100.0% |
| Q4 2019 | $18,000 | +1700.0% | 8,100 | +478.6% | 0.00% | – |
| Q2 2019 | $1,000 | 0.0% | 1,400 | -12.5% | 0.00% | – |
| Q1 2019 | $1,000 | – | 1,600 | +60.0% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 1,000 | -50.0% | 0.00% | – |
| Q3 2018 | $5,000 | -54.5% | 2,000 | -9.1% | 0.00% | -100.0% |
| Q2 2018 | $11,000 | – | 2,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |